Pulmonary Hypertension
Abstract
No abstract availableFunding Information
- National Institutes of Health (K23HL127251, KL2TR002381, P01HL108800, R01DK127083, R03AI133172, R03HL146879, R21AI156161, UL1TR002378)
- U.S. Department of Veterans Affairs (I01 BX004263, I01 CX001737)
- Cystic Fibrosis Foundation
- Merck
This publication has 11 references indexed in Scilit:
- Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factorsPulmonary Circulation, 2019
- PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidationScience Translational Medicine, 2018
- Diabetes Complications Severity Index (DCSI)—Update and ICD-10 translationJournal of Diabetes and its Complications, 2017
- medflex: An R Package for Flexible Mediation Analysis using Natural Effect Models2017
- A global view of pulmonary hypertensionThe Lancet Respiratory Medicine, 2016
- Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial HypertensionPulmonary Circulation, 2014
- Imputation Strategies for the Estimation of Natural Direct and Indirect EffectsEpidemiologic Methods, 2012
- Validity of the primary care diagnosis of diabetes in veterans in the southeastern United StatesDiabetes Research and Clinical Practice, 2011
- Insulin resistance in pulmonary arterial hypertensionEuropean Respiratory Journal, 2008
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004